Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Gilenya® (fingolimod) – Expanded indication
May 12, 2018 - Novartis announced the FDA approval of Gilenya (fingolimod), for the treatment of relapsing forms of multiple sclerosis (MS) in patients 10 years of age and older.
